Genmab's Rina-S Shows 45.9% ORR in Platinum-Resistant Ovarian Cancer
GMAB sits 47% above its 52-week low of $23.62 on elevated volume (2.1× avg).
Summary
Genmab reported Phase 2 data for its ADC Rina-S in platinum-resistant ovarian cancer: 45.9% confirmed ORR, 12.1-month median duration of response, and 9.5-month median PFS in 109 heavily pretreated patients. Responses occurred regardless of FRα expression and in patients who had prior mirvetuximab. This is the first PFS data for the program and supports the ongoing Phase 3 trials. The stock is trading near its 52-week high, so the market may have partially priced in positive data, but the durability and breadth of response are clinically meaningful. Watch for updates from the four Phase 3 RAINFOL trials, which could expand the addressable patient population.
At the time of this announcement, GMAB was trading at $34.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.2B. The 52-week trading range was $23.62 to $35.91. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.